American College of Cardiology

Justin Davies, MBBS, MRCP, PhD, discussed the cost-effectiveness analysis of the DEFINE-FLAIR trial comparing iFR and FFR for patients requiring PCI.

Incorporating underused, but available, imaging technologies like PET/CT to test for calcium in coronary arteries more precisely predicts those at risk for MI and similar threats.

While copayment reduction significantly affected clinician’s choice of medication and improved patient persistence with treatment, it did not impact clinical outcomes at 1 year.

Larry Allen, MD, was part of a deeper look into the hospital readmissions reduction program (HRRP), and what the data that have been presented about it actually mean.

For patients with heart failure, the influenza vaccine can result in a mortality reduction up to 50% in season and 20% out of season.

Listening to music may help prolong exercise and participation, and may possibly have broader implications for exercise.

Findings suggest climate change may increase MI risk.

The risk of myocardial infarction was 2.4-fold higher in patients on short-term P2Y12 inhibitors after 18 months and 5.1-fold higher from month 6 to month 18.

Andexanet was shown to reduce FXa inhibition activity by 91% for patients on apixaban, 88% for patients on rivaroxaban, and 75% for patients on enoxaparin.

No events of primary endpoint occurred in PFO closure arm, whereas it developed in 6 of 60 patients receiving medication therapy alone.

Aggressive supplementation with vitamin D3 just before and after surgery can completely eliminate the observed drop.

As canakinumab lowers hsCRP, as well as interleukin-6, without a negative effect on lipid levels, it characterizes a new class of atherosclerosis medications.

The combined efforts of coaxing from barbers and monthly in-shop care from pharmacists resulted in 63.6% of the cohort achieving target BP levels.

At 6 weeks 68% of those receiving the Triple Pill achieved a blood pressure within their target range, versus 44% of those receiving usual care.

The CVD-REAL 2 study found that compared with other glucose-lowering drugs, SGLT-2 inhibitors reduce all-cause death, hospitalization for heart failure, myocardial infarction, and stroke.

While receiving a large dose of statin therapy did not have an impact on major adverse cardiac events among a broad population of patients, those that underwent percutaneous coronary intervention saw reductions.

Patients that were more optimistic had fewer heart-related hospital visits.

The mSToPS trial revealed a wearable ECG patch can markedly increase the AFib diagnosis rate relative to routine care—as much as 9-fold in the short-term and 3-fold in the long-term.

MOMENTUM 3 found that advanced heart-failure patients with an implanted centrifugal-flow circulatory pump had lower rates of pump-related blood clots and stroke.

Studies reveal short- and long-term effects of heart changes in college and professional football players.

The use of instantaneous wave-free ratio can reportedly save each patient at least $800 in comparison with fractional flow reserve.

While full parity may be impossible, a 4-step protocol did decrease discrepancies in clinical outcomes and mortality between men and women.

Clinicians have been shown to be influenced by their patients’ genetic makeup when prescribing antiplatelet therapies.

All-cause mortality and death due to stroke, however, were 1.8% and 0.5% lower, respectively, in the group utilizing WCD.

Study sheds new light on potential risks and benefits of aspirin for people with both conditions.

The trial showed alirocumab reduced MACE by 24% with an ARR of 3.4% and all-cause death by 29% with an ARR of 1.7% in patients with ACS and baseline LDL-C ≥100 mg/dL.

Using the database from the 40-country, double-blind phase 3 ARISTOTLE study, which has been around for over 5 years, a sub-analysis was conducted by Renato Lopes, MD, PhD, professor of Medicine at Duke University in Durham, North Carolina and colleagues.

THe ACC's meeting offered studies likelcc200y to impact clinical practice.

It’s a discussion that even the most seasoned physicians might struggle with—when is it time to talk end-of-life care? Ami Bhatt, MD, director of the Adult Congenital Heart Disease Program at Massachusetts General Hospital (MGH) explained both sides of the debate for patients with adult congenital heart disease.

Some women may have suffered with cardiovascular problems since birth while others don’t find out until pregnancy unmasks the condition. Doreen DeFaria Yeh, MD, discusses the importance of merging physicians from cardiology and obstetrics.